The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients.
Future Oncol
; 17(9): 1097-1104, 2021 Mar.
Article
in English
| MEDLINE | ID: covidwho-1067596
ABSTRACT
We presented the rationale for the use of thymosin α1 as prophylaxis of severe COVID-19 in cancer patients undergoing active treatment, constituting the background for the PROTHYMOS study, a prospective, multicenter, open-label, Phase II randomized study, currently in its start-up phase (Eudract no. 2020-006020-13). We aim to offer new hope for this incurable disease, especially to frail patient population, such as patients with cancer. The hypothesis of an effective prophylactic approach to COVID-19 would have immediate clinical relevance, especially given the lack of curative approaches. Moreover, in the 'COVID-19 vaccine race era' both clinical and biological results coming from the PROTHYMOS trials could even support the rationale for future combinatorial approaches, trying to rise vaccine efficacy in frail individuals.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Thymalfasin
/
COVID-19
/
COVID-19 Drug Treatment
/
Neoplasms
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Topics:
Long Covid
/
Vaccines
Limits:
Humans
Language:
English
Journal:
Future Oncol
Year:
2021
Document Type:
Article
Affiliation country:
Fon-2020-0754
Similar
MEDLINE
...
LILACS
LIS